Ever since the development of the first vaccine more than 200 years ago, vaccinations have
greatly decreased the burden of infectious diseases worldwide, famously leading to the …

Human diseases, particularly infectious diseases and cancers, pose unprecedented
challenges to public health security and the global economy. The development and …

Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 …

Neutralizing antibodies have become an important tool in treating infectious diseases.
Recently, two separate approaches yielded successful antibody treatments for Ebola—one …

Patients with Coronavirus disease 2019 exhibit low expression of interferon-stimulated
genes, contributing to a limited antiviral response. Uncovering the underlying mechanism of …

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option
against COVID-19. Because rapidly emerging virus mutants are becoming the next major …

T cell responses play an important role in protection against beta-coronavirus infections,
including SARS-CoV-2, where they associate with decreased COVID-19 disease severity …

The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid
development of an efficient and cost-effective vaccine, suitable for mass immunization. Here …

We describe a new reverse-genetics system that allows one to efficiently generate influenza
A viruses entirely from cloned cDNAs. Human embryonic kidney cells (293T) were …

The threat of the current coronavirus disease pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential …